Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals, Inc. (CMPI) priced its initial public offering on Aug 7, 2020 at $15.00 per share, within its $14.00–$16.00 range, raising $75M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $321.6M. BofA Securities was lead-left underwriter, joined by Jefferies, BMO Capital Markets and BTIG. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy for cancer. Its candidate, CMP-001, is a Toll-like receptor 9 agonist delivered as a virus-like particle and injected into tumors, and showed a 28% best objective response rate alongside a checkpoint inhibitor in patients unresponsive to one.

Status

IPO

Ticker

CMPI

Exchange

Nasdaq Global Market

Priced

Aug 7, 2020

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$75M

Market cap at IPO price

$321.6M

First filed

Jul 17, 2020

Underwriters

BofA Securities, Jefferies, BMO Capital Markets and BTIG

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.